Skip to content

Michael Brenner, of Harvard Medical School, joins Scailyte as advisor

Professor Michael Brenner joins Scailyte

Michael Brenner joins Scailyte

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Michael Brenner MD, Elizabeth Fay Brigham Professor of Medicine at Harvard Medical School, joins Scailyte as an advisor to the Board of Directors.

Prof. Brenner is the director of Brigham and Women’s Hospital’s Human Immunology Center, which creates and performs single-cell transcriptional analysis and functional investigations in order to decipher human autoimmune illnesses, stratify patient groups, and find prospective therapeutic target cells and pathways. He is a member of the National Academy of Sciences in the United States and has received numerous awards.

Prof Brenner’s research focuses on T cell biology, antigen presentation, microbial pathogenesis, and autoimmunity. His research discovered the integrin molecule aEb7 (CD103) and its role in leukocyte homing, as well as a role for the CD1 antigen presentation system in the activation of T cells and NKT cells. His team has recently identified distinct fibroblast subpopulations that are pathologically expanded in disease, as well as a new T helper cell population, T peripheral helper (Tph) cells, that are implicated in antibody production in autoantibody-mediated disorders.

Michael Brenner, MD comments: “I am thrilled to support Scailyte in their pioneering efforts combining single-cell technologies and artificial intelligence for biomarker discovery. Single-cell technology is moving into the clinical space and Scailyte is there at the right moment to capture the potential and create a new generation of clinical applications that will make a difference for patients.”

About Scailyte

Scailyte is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Scailyte’s proprietary best-in-class data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision is the most powerful and cutting-edge approach to develop methods for precise diagnosis and prediction of therapy response. Scailyte leverages a global network of clinicians to identify disease indications with high unmet needs and collaborates with global pharmaceutical and biotech companies to translate the novel biomarkers into ultra-sensitive companion diagnostics (CDx) and IVD assays. 

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

Recent News

ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology

Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...

Read more

Recent News

Pitch-nic Expo

We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...

Read more

Recent News

Targets & Cell Types in Immuno-Oncology Europe 2023

Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...

Read more

Recent News

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

Recent News

NextGen Omics 2023

Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...

Read more

Recent News

SITC 2023

Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...

Read more

Recent News

ScaiDigest Volume 5: Unlocking the Secrets of AML

Read Diana's insightful post and stay at the forefront of scientific advancements in the field!

Read more

Recent News

01 /04

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology

Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...

Read more

Recent News

02 /04

Pitch-nic Expo

We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...

Read more

Targets & Cell Types in Immuno-Oncology Europe 2023

Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...

Read more

Recent News

03 /04

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

NextGen Omics 2023

Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...

Read more

Recent News

04 /04

SITC 2023

Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...

Read more

ScaiDigest Volume 5: Unlocking the Secrets of AML

Read Diana's insightful post and stay at the forefront of scientific advancements in the field!

Read more

Recent News